Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes
Shots:
- The P-III SURPASS-2 trial involves assessing Tirzepatide (5/10/15mg) vs Semaglutide (1mg) in 1-879 patients in a ratio (1:1:1:1) with T2D inadequately controlled with ≥1500 mg/day metformin alone for 40wks.
- Results: A1C reduction: (-2.09% /-2.37%/-2.46% vs- 1.86%); Weight reduction: (-7.8/-10.3/-12.4kg vs -6.2 kg); patients achieving A1C <7% (5.5%/88.9%/ 92.2% vs 81.1%); patients achieving A1C <5.7% (29.3% /44.7%/50.9% vs 19.7%) respectively
- The highest & lowest doses of therapy (15 & 5mg) led to an A1C reduction of 2.46 % & 2.09% with a reduction in body weight by 12.4 kg (13.1 %) & 7.8 kg (8.5%). Thus- all three doses of Tirzepatide showed a reduction in A1C and body weight
Ref: Lilly | Image: BioSpace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com